Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Dec 6:13:1055248.
doi: 10.3389/fphar.2022.1055248. eCollection 2022.

Research progress on effects of traditional Chinese medicine on myocardial ischemia-reperfusion injury: A review

Na Xing  1   2 , Xiao-Tong Long  1   3 , Hui-Juan Zhang  1   4 , Li-Dan Fu  1   4 , Jian-Yuan Huang  1   5 , Abdallah Iddy Chaurembo  1   2   6 , Francis Chanda  1   2   6 , Yun-Jing Xu  1   2   6 , Chi Shu  1   7 , Kai-Xuan Lin  8   9 , Ke Yang  1   10 , Han-Bin Lin  1   2   6
Affiliations
Review

Research progress on effects of traditional Chinese medicine on myocardial ischemia-reperfusion injury: A review

Na Xing et al. Front Pharmacol. .

Abstract

Ischemic heart disease (IHD) is a high-risk disease in the middle-aged and elderly population. The ischemic heart may be further damaged after reperfusion therapy with percutaneous coronary intervention (PCI) and other methods, namely, myocardial ischemia-reperfusion injury (MIRI), which further affects revascularization and hinders patient rehabilitation. Therefore, the investigation of new therapies against MIRI has drawn great global attention. Within the long history of the prevention and treatment of MIRI, traditional Chinese medicine (TCM) has increasingly been recognized by the scientific community for its multi-component and multi-target effects. These multi-target effects provide a conspicuous advantage to the anti-MIRI of TCM to overcome the shortcomings of single-component drugs, thereby pointing toward a novel avenue for the treatment of MIRI. However, very few reviews have summarized the currently available anti-MIRI of TCM. Therefore, a systematic data mining of TCM for protecting against MIRI will certainly accelerate the processes of drug discovery and help to identify safe candidates with synergistic formulations. The present review aims to describe TCM-based research in MIRI treatment through electronic retrieval of articles, patents, and ethnopharmacology documents. This review reported the progress of research on the active ingredients, efficacy, and underlying mechanism of anti-MIRI in TCM and TCM formulas, provided scientific support to the clinical use of TCM in the treatment of MIRI, and revealed the corresponding clinical significance and development prospects of TCM in treating MIRI.

Keywords: cardioprotective effects; molecular mechanisms; myocardial ischemia–reperfusion injury; pathogenesis; traditional Chinese medicine.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

FIGURE 1
FIGURE 1
Mechanisms of programmed cell death of MIRI.
FIGURE 2
FIGURE 2
TCM formulas, single Chinese herbs, and active compounds that protect the heart from MIRI.
FIGURE 3
FIGURE 3
TCM anti-MIRI effects and their respective pathways.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Andrienko T. N., Pasdois P., Pereira G. C., Ovens M. J., Halestrap A. P. (2017). The role of succinate and ROS in reperfusion injury -A critical appraisal. J. Mol. Cell. Cardiol. 110, 1–14. 10.1016/j.yjmcc.2017.06.016 - DOI - PMC - PubMed
    1. Bai S., Wang X., Wu H., Chen T., Li X., Zhang L., et al. (2021). Cardioprotective effect of anisodamine against ischemia/reperfusion injury through the mitochondrial ATP-sensitive potassium channel. Eur. J. Pharmacol. 901, 174095. 10.1016/j.ejphar.2021.174095 - DOI - PubMed
    1. Bai X. J., Ren J. X. (2014). The treatment of No-reflow occurring during percutaneous coronary intervention on the pathogenesis of insidious phlegm. Chin. J. Exp. Traditional Med. Formulae 20 (16), 237–240. 10.13422/j.cnki.syfjx.2014160237 - DOI
    1. Billah M. M., Khan F., Niaz K. (2019). Scutellaria baicalensis Georgi. Nonvitamin Nonmineral Nutr. Suppl. 2019, 403–408. 10.1016/B978-0-12-812491-8.00054-0 - DOI
    1. Bittl J. A., Tamis-Holland J. E., Lawton J. S. (2022). Does bypass surgery or percutaneous coronary intervention improve survival in stable ischemic heart disease? JACC. Cardiovasc. Interv. 15 (12), 1243–1248. 10.1016/j.jcin.2022.05.011 - DOI - PubMed